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Abstract 
Background: The effectiveness of World Health Organization (WHO) guidelines for 
pneumonia case management in sub-Saharan Africa has been contested. This thesis 
aims to determine the clinical effectiveness of these guidelines among children 
admitted to Kenyan hospitals in a period after the introduction of the pneumococcal 
and Haemophilus influenzae type B (Hib) conjugate vaccines. The studies focus on 
the treatment of children with chest indrawing pneumonia, who were previously 
regarded to be at high-risk requiring inpatient treatment but were reclassified as low-
risk (non-severe) in the WHO guidelines updated in 2013. 
Methods: This thesis consists of: (i) A systematic review linked to a national guideline-
development exercise appraising the evidence for the WHO pneumonia guidelines, (ii) 
a prospective observational study evaluating adherence to, and effectiveness of the 
pneumonia guidelines in the national referral hospital in Kenya, (iii) a multi-centre 
pragmatic randomised controlled trial (RCT) comparing amoxicillin versus benzyl 
penicillin for chest indrawing pneumonia (iv) a cohort study comparing treatment 
effects among children enrolled in the antibiotic RCT with a similar group who received 
routine care, and (v) a  multi-centre retrospective cohort study of children hospitalised 
with pneumonia describing factors associated with mortality, focusing on 
characteristics that increase risk of death among children who would, under current 
guidance, be assigned a non-severe classification. 
Results: Although evidence from clinical trials supported the adoption of oral 
amoxicillin for severe pneumonia over benzyl penicillin (the standard treatment) for 
chest indrawing pneumonia, a Kenyan guideline development panel raised concerns 
of generalizability citing the limited data from sub-Saharan African populations in whom 
mortality was argued to be high. This concern was explored using prospectively-
collected observational data from 385 children. Treatment failure and mortality were 
infrequent (<2%) for chest indrawing pneumonia where strict definitions requiring 
documented evidence of clinical deterioration were applied. In comparison, high rates 
of treatment failure (21.4%) and mortality (10.5%) were observed for severe 
pneumonia (formerly very severe pneumonia). Using propensity scores to model 
treatment effects comparing guideline recommended regimens with more costly, 
broad-spectrum alternatives, similar risks of treatment failure were observed in both 
groups. Amoxicillin was compared with benzyl penicillin in a pragmatic clinical trial of 
527 children that also revealed low and comparable risks of treatment failure (8%) and 
mortality (<1%) for the two treatments. Consistent results were observed in an 
observational cohort of children hospitalised at the same health facilities over the 
period the trial was conducted. However, analyses of data from >16000 children 
suggested that the presence of commonly-occurring clinical signs may be associated 
with increased risk among children with non-severe pneumonia. Specifically, very low 
weight-for-age Z score (WAZ) or pallor in children with non-severe pneumonia were 
shown to be associated with absolute risks of mortality as high as those for severe 
pneumonia. 
Conclusions: Findings from locally-conducted observational studies and a clinical trial 
indicate low risks of treatment failure and mortality among children with chest 
indrawing pneumonia following treatment with benzyl penicillin monotherapy or 
amoxicillin. In contrast, mortality for severe pneumonia was greater than 10 percent. 
These results are consistent with the updated WHO recommendations and have more 
recently informed the revision of the national policy for pneumonia case management 
in Kenya. However, these guidelines may apply to sub-populations of children with 
non-severe pneumonia and either very low WAZ or pallor. This evidence is expected 
to contribute to ongoing debates on the adoption of WHO guidance for pneumonia 
case management in similar settings across sub-Saharan Africa where coverage of 
the Hib and pneumococcal conjugate vaccines is high.
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1 Introduction 
Child mortality has declined substantially over recent decades; however, pneumonia 
continues to claim the lives of almost one million children annually. Over half of the 
global pneumonia-related deaths occur in sub-Saharan Africa (1, 2). Empirical 
treatment of children with clinically-suspected pneumonia using simple antibiotics is a 
major component in a package of evidence-based interventions promoted by the World 
Health Organization (WHO), UNICEF and other development partners to reduce 
mortality due to pneumonia (3). This strategy, widely referred to as case management, 
is founded on four basic assumptions: (i) a high proportion of fatal pneumonia is of 
bacterial origin (mostly Haemophilus influenzae type B (Hib) and Streptococcus 
pneumoniae), (ii) timely antibiotic therapy of these infections substantially reduces 
pneumonia case fatality, (iii) an algorithm based on simple clinical signs is sensitive 
and adequately specific in identifying children with pneumonia requiring antibiotic 
therapy, and (iv) health workers can use this algorithm and provide antibiotics to 
children (4). The effectiveness of this strategy has been studied widely with 
independent reports estimating that antibiotic treatment alone for severe forms of 
pneumonia may result in a 6 – 15 percent reduction in mortality (5, 6). Prior to the most 
recent revision of the WHO case management guidelines, a common clinical algorithm 
was adopted across all the major WHO regions and remained largely unchanged for 
almost 30 years. Under these guidelines, children with a history of a cough and 
difficulty in breathing were assigned to one of four levels of severity (including no 
pneumonia) based on presenting clinical signs. It is these signs that then informed the 
choice of empirical antibiotic treatment (Table 1).  
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Table 1: WHO (2005) guidelines for the management of children aged 2 - 59 
months with a cough and/or difficulty breathing 
Syndrome* Clinical Signs Recommended Antibiotic 
Treatment  
Very severe 
pneumonia 
Any one of: cyanosis, grunting, 
inability to drink, altered 
consciousness 
Inpatient treatment  
Benzyl penicillin/ ampicillin and 
gentamicin  
(plus high dose co-trimoxazole for 
all HIV-exposed) 
Severe 
pneumonia 
Lower chest wall indrawing 
AND without signs of very severe 
pneumonia 
Inpatient treatment  
Benzyl penicillin/ ampicillin 
monotherapy (if HIV-exposed, treat 
as very severe pneumonia) 
Non-severe 
pneumonia 
Fast breathing (RR≥50/min if age 
2-11months; ≥40/min if age 12-
59 months) 
AND without signs of severe or 
very severe pneumonia 
Outpatient treatment 
Co-trimoxazole (or amoxicillin if 
child has HIV and is receiving co-
trimoxazole prophylaxis) 
*For a child without stridor, severe acute malnutrition or signs of meningitis 
 
Inpatient treatment with injectable antibiotics was reserved for children with severe and 
very severe classifications of pneumonia while children with “non-severe pneumonia” 
were to be managed at home with oral antibiotics (7). 
 
In the following section (Section 2), I present a background to the issues tackled in this 
thesis, before providing the historical basis of the WHO case management guidelines 
in Section 3, and a brief description of the published aetiological studies on childhood 
pneumonia in Section 4. In Section 5, I outline some of the important risk factors that 
may account for variability in clinical outcomes of treatment over recent years and 
across populations under the existing case management guidelines, focusing on 
children in sub-Saharan Africa. I then summarise the individual publications that 
contribute to this thesis in Section 7 and finally present a discussion (Section 8), 
highlighting important areas for further research in the field in Section 9.    
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2 Background to the thesis 
For the most recent revision of the guidelines for treatment of childhood illnesses, 
WHO adopted an evidence-driven approach to generate recommendations that were 
eventually incorporated in the updated Pocket Book for the Management of Sick 
Children (8). In this exercise, the Grading of Recommendations Assessment 
Development and Evaluation (GRADE) methodology was used to systematically 
appraise and rank existing evidence based on the quality of the primary studies, and 
ultimately develop recommendations after considering local contextual factors (9). 
In what is widely regarded a major revision in the WHO guidelines for management of 
childhood pneumonia, the guideline development panel made a strong 
recommendation based on moderate quality evidence that children with indrawing 
pneumonia without danger signs should be treated as outpatients with oral amoxicillin 
– effectively downgrading their classification from severe to non-severe (Table 1). This 
decision was primarily based on evidence from three clinical trials comparing treatment 
effects of benzyl penicillin versus oral amoxicillin (10-12) and after considering 
additional factors including risks, benefits, acceptability and feasibility of adopting oral 
amoxicillin. 
 
Researchers, policymakers and clinicians across sub-Saharan Africa have expressed 
reluctance to adopt these revised recommendations, citing concerns that the 
population of children presenting with indrawing pneumonia in Africa may experience 
poorer outcomes than those who were enrolled in the studies that eventually informed 
the WHO revised guidelines (13). Indeed, results from observational studies indicate 
that despite the guidelines being widely available, clinicians in Kenya frequently 
prescribe alternative, perceivably “stronger” antibiotics, presumably due to doubts 
regarding the effectiveness of the recommended treatment regimens (14, 15). 
These concerns are supported by evidence from studies showing wide regional 
variation in the risk of death among children with pneumonia. In a systematic review 
of 37 published observational studies of children ranging from 0 – 59 months old 
hospitalised with pneumonia, reported case fatality was 0.4 percent in industrialized 
countries, 2.1 percent in southeast Asia and 3·9 percent in Africa (16) (Table 2). These 
data suggest that pneumonia-related mortality may be higher in sub-Saharan Africa 
than in other regions of the world including Asia, where the bulk of the data that 
informed the recent WHO pneumonia guideline updates were drawn from (8). 
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Table 2: Case fatality rates for severe acute lower respiratory infections in children younger than five years by region 
Adapted from Nair et al. 2013(16))  CFR – Case Fatality Rate  CI – Confidence interval 
Region Aged 0 – 11 months  Aged 12 – 59 months  Aged 0 – 59 months 
 Studies CFR (95% CI)   Studies CFR (95% CI)  Studies CFR (95% CI) 
Africa 9 3·8% (2·4–5·9)  8 1·9% (1·2–3·2)  11 3·9% (2·7–5·5) 
Americas 10 1·6% (1·1–2·4)  10 0·6% (0·2–1·3)  11 1·3% (0·8–1·9) 
Europe - -  - -  1 0·4% (0·3–0·5) 
Southeast Asia 6 2·6% (1·4–4·7)  4 0·3% (0·1–0·9)  9 2·1% (1·1–4) 
Western Pacific 1 2·4% (1·3–4·3)  - -  3 2·3% (1·7–3·2) 
Developing 25 2·4% (1·7–3·6)  21 0·8% (0·4–1·3)  32 2·3% (1·6–3·4) 
Industrialized 1 0·8% (0·7–0·9)  1 0·3% (0·2–0·5)  3 0·6% (0·4–0·8) 
Global 26 2·3% (1·5–3·4)  22 0·7% (0·4–1·2)  35 2·1% (1·4–3·1) 
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There is, therefore, uncertainty regarding the effectiveness of the global guidance for 
antibiotic therapy of pneumonia in Africa, fuelled by factors that are believed to have 
altered the epidemiology and clinical severity of pneumonia since the guidelines were 
introduced. Among these factors are: (i) Introduction of vaccines targeting 
Haemophilus influenzae type B and Streptococcus pneumoniae – previously the 
leading causes of bacterial pneumonia in children, (ii) changing prevalence of major 
risk factors for mortality in pneumonia, particularly HIV and possibly malnutrition, and 
(iii) increasing resistance to the antibiotics used for treating pneumonia. In addition, 
there are questions concerning the external validity of evidence derived from 
equivalence / non-inferiority clinical trials comparing antibiotics for pneumonia to 
routine clinical settings. Specifically, concerns have been raised regarding the very 
low case-fatality rate among clinical trial patients suggesting biased selection of 
children with lower severity of illness and the potential role of the so-called “Pollyanna 
Phenomenon” in antibiotic studies resulting from a “dilutional effect” of patients with 
self-limiting disease e.g. viral illness, who recover regardless of care, thus steering 
trial results towards equivalence (13, 17, 18). 
To further expound on the bases of these controversies that may account for the 
hesitancy in adoption and implementation of the WHO guidelines in Kenya and other 
sub-Saharan African countries, a background to the original case management 
guidelines is provided in the following section.  
 
3 Historical overview of WHO pneumonia case 
management 
Recognizing the need to address the enormous burden of childhood pneumonia in 
developing countries a meeting was convened by WHO to develop a structured 
approach to the management of children with acute lower respiratory tract infections 
in low-level facilities (19) in 1980. At this meeting, initial draft of the algorithm for the 
management of childhood pneumonia that was subsequently adopted across 
developing countries approximately ten years later was shared. The primary 
evidence that informed the assignment of the severity classifications still currently in 
use in many countries today draws from work conducted in Papua New Guinea 
describing possible criteria for identifying children with acute respiratory infections 
requiring antibiotics and inpatient care (20). In this study, 350 children aged 0 – 59 
months were enrolled prospectively using the presence of crepitations to define those 
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who required antibiotics. Fast breathing was determined to have high specificity and 
sensitivity for identifying children requiring antibiotics. Lower chest wall indrawing 
was identified in all 50 children hospitalised with pneumonia with crepitations. This 
finding formed the basis of the current recommendation for inpatient treatment for 
children with indrawing. In a later study, the same team sought to validate the severity 
classification of pneumonia in a cohort of 748 children aged above 28 days admitted 
at three hospitals with WHO-defined severe forms of pneumonia. The overall 
mortality rate observed was 15 percent. Clinical signs that were found to be strongly 
associated with mortality in univariate analyses included the presence of malnutrition, 
cyanosis, duration of illness of five or more days, the absence of fever (among 
malnourished children), and inability to feed. Severe indrawing and grunting were 
weakly associated with mortality (P<0.06) while tachypnoea (respiratory rate >70 
breaths per minute) showed no association with mortality (21). In a more recent 
review of six studies discussing the diagnostic utility of the WHO pneumonia case 
management clinical signs in predicting radiological pneumonia, sensitivity of 
tachypnoea ranged from 72 percent to 94 percent with specificities between 38 
percent and 99 percent, while chest indrawing had reported sensitivities of between 
46 percent and 78 percent (22). The authors of this review further report clinically-
defined improvement 48 hours into treatment in at least 80 percent of children treated 
using recommended antibiotics, suggesting effectiveness of the guideline regimens. 
The lack of standardised definitions for clinical success or treatment failure in 
pneumonia is however acknowledged as a general limitation in this, and other studies 
(23, 24). 
 
4 Aetiological studies on childhood pneumonia 
Reliable data on the causes of pneumonia are scarce for several reasons: (i) The 
“gold standard tests” for microbiological diagnosis (lung aspirates and biopsy) are 
technically demanding, risky, invasive procedures. (ii) The yield from the traditional 
method of microbiological diagnosis using bacterial blood cultures is low, ranging 
from 1 – 7 percent (25, 26)  (iii) Many patients present to hospital after having 
received antibiotics, further limiting the yield of available diagnostic tests. (iv) There 
is often difficulty distinguishing harmless commensal organisms from pathogens. 
Interpretation of results across studies is complicated further by the poor 
standardisation of case definitions and procedures (27).  
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The empirical antibiotic regimen for treatment of childhood pneumonia is based on a 
number of small studies summarised in a review of lung aspiration studies conducted 
in developing countries published in 1986 (28), several years prior the introduction of 
the pneumococcal and Haemophilus influenzae type B conjugate vaccines. A total of 
13 studies conducted in 8 countries recruiting 1029 children were reviewed. Of these, 
640 (62 percent) yielded positive bacterial cultures. The most frequently isolated 
organisms were Streptococcus pneumoniae (27 percent), Haemophilus influenzae 
(27 percent) and Staphylococcus aureus (17 percent). While this work provided 
valuable evidence on the causes of pneumonia in children, the primary studies had 
serious methodological limitations including the variability of case definitions used 
and the lack of appropriate control groups. These results were later supported in a 
large longitudinal study undertaken from 1985 – 1989 in ten low-income countries 
(29). In this project coordinated by the Board on Science and Technology for 
International Development (BOSTID), cohorts of children aged 0 – 59 months were 
recruited prospectively in both outpatient and inpatient departments. Data on 
sociodemographic and clinical characteristics, incidence, duration, prevalence and 
case fatality of respiratory tract infections were recorded for all patients. Specimens 
were also collected from a selected group of patients to study the aetiology of 
respiratory infections. Viruses were found to be more common than bacteria as 
causes of lower respiratory tract infections (14 – 64 percent versus 4.5 – 40 percent). 
However, the failure to obtain lung aspirate samples in this study may have reduced 
the ability to detect bacterial organisms. The most common bacterial organisms were 
Streptococcus pneumoniae followed by Haemophilus influenzae at all sites except in 
Pakistan where H. influenzae was more frequent.  
Numerous smaller studies have been undertaken in a variety of settings since the 
BOSTID studies. In a survey of studies conducted between 2000 and 2010, 65 
childhood pneumonia aetiology studies were identified, representing 41 countries 
(27). The wide variation in methods employed and lack of uniform case definitions 
across different studies was cited as a limitation to the potential collective utility of 
the individual studies to provide the lacking understanding of the causes of childhood 
pneumonia in the present era. Some of this information is anticipated to availed upon 
the announcement of the findings of the Pneumonia Etiology Research for Child 
Health (PERCH) project – a large rigorously conducted multicountry case control 
pneumonia aetiological study designed specifically to identify the expected etiologies 
of pneumonia in the period post-introduction of the pneumococcal and Hib vaccines 
(30). Available results from a pre-pneumococcal, post- H. influenzae type B vaccine 
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pilot study of 810 PERCH study participants in coastal Kenya showed a statistically 
significant association with hospitalisation (odds ratio, 12.5; 95 percent confidence 
interval, 3.1–51.5) for nasopharyngeal isolation of Respiratory Syncytial virus (RSV). 
However, the clinical significance of most viruses identified was not clear, given the 
high prevalence of viral detection in controls. Among 728 patients with both blood 
culture and HIV testing performed, a positive culture was more common among HIV-
positive patients (14/69; 20 percent) than those who were HIV negative (36/659; 5 
percent) (P<.001). Bacteria isolated in blood culture were: Streptococcus 
pneumoniae (n=30), nontyphi salmonellae (n=6), H. influenzae (n=4), Escherichia 
coli (n=4), Klebsiella species (n=3), group D streptococcus (n=1), S. aureus (n=1), 
Burkholderia species (n=1), Moraxella catarrhalis (n=1), and Campylobacter jejuni 
(n=1). The investigators were unable to determine the aetiology of pneumonia for the 
32 fatal cases recruited. 
  
5 Risk factors for clinical severity and mortality among 
children with pneumonia  
Sonego et al. studied risk factors for mortality in a large systematic review of 77 
studies conducted in low- and middle-income countries including almost 200,000 
children (31). Very severe pneumonia, age below two months, Pneumocystis carinii 
infection, comorbidities including HIV infection and severe malnutrition, young 
maternal age, low maternal education, low socio-economic status, second-hand 
cigarette smoke exposure, and indoor air pollution were each independently 
associated with increased mortality. Childhood immunisation and attendance of 
antenatal care were associated with decreased odds of death. In this section, some 
of these factors that may have altered pneumonia-related mortality in Kenya and 
similar countries in the region are discussed in detail. 
 
5.1 Impact of conjugate vaccines 
Numerous studies have demonstrated the impact of both pneumococcal and Hib 
vaccines on the incidence of disease attributable to the two bacterial agents 
previously responsible for the greatest burden of childhood pneumonia. Evidence of 
effectiveness of these vaccines has been shown in both high and low-income settings 
(32-35). Epidemiological data from Kenya suggest that the introduction of the Hib 
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vaccine resulted in an 88 percent decline in invasive disease due to Hib within tree 
years of introduction (36) (Figure 2).  
 
Figure 1: Incidence of invasive Haemophilus influenzae type B (Hib) Disease at 
Kilifi District Hospital pre- and post-Hib vaccine introduction (source: Cowgill 
et al., 2006) 
 
Early data from unpublished reports from the same site indicate a similar downward 
trend in the incidence of invasive pneumococcal disease following the introduction of 
the 10-valent pneumococcal conjugate vaccine to the national routine childhood 
immunisation schedule in 2011. These findings have an important bearing on the 
prevailing aetiological agents of pneumonia (37), particularly in settings with high 
coverage of the two vaccines, such as Kenya where the most recent national survey 
reports approximately 80 percent coverage for all basic vaccines among children 
aged 12 – 23 months (38).  
 
5.2 Effect of undernutrition on pneumonia 
Undernutrition is a well-established risk factor for childhood infections including 
pneumonia and is associated with high mortality in severe cases (39-42). The 
mechanisms underlying the increased incidence of pneumonia and poor clinical 
outcomes among undernourished children are still poorly understood but are widely 
thought to be partly linked to an acquired immune deficiency (43-45). In a systematic 
review of 16 studies, children with pneumonia classified with moderate and severe 
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malnutrition invariably experienced higher risks of death (41). In one study that 
enrolled almost 10,000 children in Chile, the risk of death among malnourished 
children was 121 times higher than that for children of normal nutritional status (46). 
In eleven of the studies in the review which reported on aetiology (total of 215 positive 
bacterial isolates studied), Klebsiella pneumoniae was the most frequently isolated 
pathogen (26 percent) followed by Staphylococcus aureus (25 percent), 
Streptococcus pneumoniae (18 percent) Escherichia coli (8 percent) and 
Haemophilus influenzae (8 percent). In their conclusion, the authors challenge the 
failure of the WHO guidelines to take account of the spectrum of pathogens 
responsible for pneumonia in malnourished children.  
 
5.3 HIV infection and childhood pneumonia 
HIV-infected children experience increased risks of acquiring pneumonia (47) and an 
increased frequency of pneumonia-related death (48-51). In addition, HIV-infected 
children are susceptible to a wider spectrum of organisms causing pneumonia than 
those who are HIV negative. Mycobacterium tuberculosis and Pneumocystis jirovecii 
are notably important causes of pneumonia in HIV-infected children (48, 52). With 
current efforts towards the elimination of mother to child transmission of HIV, mainly 
through increasing the coverage of the Prevention of Mother to Child Transmission 
(PMTCT) interventions (90 percent of HIV infected mothers in 2012) (53), the 
prevalence of HIV infection among children is expected to have declined globally. 
The most recent Kenya AIDS Indicator Survey reported a prevalence of HIV infection 
of 0.9 percent among children aged 18 months to 14 years (53). As paediatric HIV 
prevalence declines, the incidence of severe forms of pneumonia and mortality 
associated with the HIV are also expected to decrease. Of importance, however, is 
the increased burden and risk of poor outcomes (death and treatment failure) among 
children who are HIV-uninfected but born to HIV-infected mothers (HIV-exposed 
uninfected children) compared to HIV uninfected (48, 54-57). The mechanisms 
underlying this association are currently poorly understood but may be related to 
socioeconomic factors linked to living in an HIV-affected household or direct 
biological effects of increased exposure to maternally infections including 
cytomegalovirus, reduced transplacental transfer of antibodies from 
immunocompromised mothers, or impaired responses to vaccines (58). 
 
    
 
11 
6 Objective 
The overarching objective of this PhD thesis is: 
to assess the effectiveness of the World Health Organization guidelines for the 
management of childhood pneumonia among hospitalised children in Kenya. 
7 Manuscripts for PhD submission 
The works consist of: (i) A systematic review describing the process and results of 
evidence synthesis undertaken for clinical questions discussed during a national 
exercise for the local adaptation of the WHO pneumonia guidelines in Kenya. (ii) A 
prospective observational study of the adherence to and effectiveness of the national 
childhood pneumonia treatment guidelines in a large tertiary hospital. In this study, I 
also describe the use of propensity scores to model treatment effects of various 
antibiotic regimens adopted by hospital clinicians. (iii) A randomised controlled trial 
(RCT) conceptually borne out of the concerns raised by the national guideline panel 
of experts (described in the systematic review) comparing the effectiveness of oral 
amoxicillin versus benzyl penicillin for the treatment of children with severe 
pneumonia in Kenya. (iv) A cohort study examining the external validity of the findings 
of the RCT using data collected from a parallel observational cohort of children with 
pneumonia who received routine care at the RCT sites. (v) A retrospective cohort 
study of children hospitalised at 14 sites with pneumonia classified using the post-
2013 WHO categories of severity (non-severe, and severe) that describes the factors 
associated with mortality, focusing on those that increase risk substantially among 
children who would be assigned a non-severe classification under current guidance. 
The five manuscripts, published in peer-reviewed journals, are summarised in the 
section below. 
 
1. Agweyu A, Opiyo N, and English M. Experience developing national evidence-
based clinical guidelines for childhood pneumonia in a low-income setting - making 
the GRADE? BMC Pediatr. 2012;12:1. 
In 2009, the Kenyan Ministry of Health requested for technical support to revise the 
national paediatric guidelines. I was responsible for conducting evidence synthesis 
for clinical questions specific to antibiotic treatment of childhood pneumonia. With 
relatively limited resources, we applied a modified form of the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) approach 
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to appraise and summarise the available evidence ahead of the guideline review 
meeting. Evidence from clinical trials, although initially ranked as high quality, 
frequently raised concerns of generalizability among the panellists based on the 
absence of studies conducted in sub-Saharan African populations in whom mortality 
was argued to be high. A notable example was the panel’s decision to vote strongly 
against adoption of oral amoxicillin for severe pneumonia over benzyl penicillin 
despite moderate quality evidence suggesting clinical equivalence between the two 
and additional factors favouring amoxicillin. In this paper, we argue that, while this 
exercise may have fallen short of the rigorous requirements recommended by the 
developers of GRADE, it represented a major improvement on previous attempts at 
guideline development in low-income countries and offers valuable lessons for future 
similar exercises where resources and locally-generated evidence are scarce. 
 
2. Agweyu A, Kibore M, Digolo L, Kosgei C, Maina V, Mugane S, Muma S, Wachira 
J, Waiyego M,  and Obimbo E. Prevalence and correlates of treatment failure among 
Kenyan children hospitalised with severe community-acquired pneumonia: a 
prospective study of the clinical effectiveness of WHO pneumonia case management 
guidelines. Trop Med Int Health. 2014;19(11):1310-20. 
Against a background of limited local evidence on the effectiveness of the WHO 
pneumonia case management guidelines, I led a team of investigators in conducting 
a prospective observational study on the clinical outcomes of pneumonia in a large 
teaching hospital in Nairobi, Kenya. In this study of 385 children, treatment failure 
was heavily influenced by early changes in therapy by clinicians in the absence of an 
obvious clinical rationale. Where a strict definition of treatment failure requiring 
documented evidence of clinical deterioration was applied, low rates of failure were 
observed. Non-adherence to treatment guidelines was common (41 percent of 
children with severe pneumonia and 33 percent those with very severe pneumonia). 
Taking advantage of the large number of children who were treated with non-
standard regimens, I used propensity scores to model treatment effects comparing 
guideline recommended regimens with more costly, broad-spectrum alternatives 
used while accounting for imbalances in the distribution of baseline characteristics 
that may have influenced clinician treatment choices. In these exploratory analyses, 
similar risks of treatment failure were observed in both groups. In my conclusions, I 
am careful to state the limitations of the findings and recommend appropriately 
designed pragmatic trials to address clinical questions of this nature. 
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3. Agweyu A, Gathara D, Oliwa J, Muinga N, Edwards T, Allen E, Obimbo E, and 
English M, on behalf of the Severe Pneumonia Study Group. Oral amoxicillin versus 
benzyl penicillin for severe pneumonia among Kenyan children: a pragmatic 
randomized controlled noninferiority trial. Clin Infect Dis. 2015;60(8):1216-24. 
While clinical trials conducted in predominantly Asian populations demonstrating 
clinical equivalence between amoxicillin and benzyl penicillin led to a revision of the 
WHO pneumonia guidelines in 2013, Kenyan policymakers declined to support a 
change in the guidelines in the absence of supporting evidence from African 
populations citing concerns of high mortality in Africa. Details of the national guideline 
development exercise which involved over 70 experts form clinical, policy and 
academic backgrounds are provided in the first paper summarized above (Agweyu 
et al. 2012). In response to this gap in evidence, I led a team in designing and 
conducting a multi-centre pragmatic clinical trial to compare the effectiveness of the 
two antibiotics. A total of 527 children aged 2–59 months with severe pneumonia as 
defined in the 2005 WHO guidelines were recruited from 6 public hospitals across 
Kenya. The risk of treatment failure was 7.7 percent in the amoxicillin arm and 8.0 
percent in the benzyl penicillin arm at 48 hours in per-protocol analyses (risk 
difference, −0.3 percent [95 percent confidence interval, −5.0 percent to 4.3 
percent]), indicating non-inferiority within the pre-specified margin of 7 percent at 48 
hours. Similar results were obtained in intention-to-treat analyses. Mortality was low 
(0.8 percent) and comparable to reported findings of the previous trials conducted in 
Asia that informed the WHO technical updates in 2013. The findings of this study 
offer important evidence for policymakers in sub-Saharan African considering the 
local adaptation of the recent global recommendations for the management of 
childhood pneumonia. 
 
4. Agweyu A, Oliwa J, Gathara D, Muinga N, Allen E, Lilford RJ, and English M. 
Comparable outcomes among trial and nontrial participants in a clinical trial of 
antibiotics for childhood pneumonia: a retrospective cohort study. J Clin Epidemiol. 
2018;94. 
Evidence derived from well-conducted randomised controlled trials (RCTs) is 
generally regarded to be of high quality. However, critics often argue that the strict 
enrolment criteria and intensive follow up of patients enrolled in clinical trials 
compromise the generalizability of the findings to routine care settings. In public 
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hospitals in many low- and middle-income countries, the quality of care delivered to 
patients in routine settings is substantially poorer than that provided for patients 
enrolled in clinical trials (regardless of treatment allocation). In this paper, I seek to 
compare mortality among children enrolled in the RCT comparing the effectiveness 
of two antibiotics for severe childhood pneumonia described above (Agweyu et al, 
2015), with a similar observational cohort of children hospitalised at the same health 
facilities over the period the trial was conducted. Out of 1709 eligible children, 30.8 
percent were enrolled in the RCT. No difference was observed in mortality between 
the two groups in unadjusted analyses comparing RCT versus non-RCT participants 
(OR 0.6; 95 percent CI 0.2 to 1.9). Similar results were found in adjusted models 
using multiple imputation to account for missing data. In the discussion, I highlight 
the utility of the findings of this study for policymakers considering the generalizability 
of evidence from clinical trials suggesting low mortality among children with severe 
pneumonia. I also describe the methodological limitations of using routine data for 
policy making, particularly in settings where health information systems are weak. 
 
5. Agweyu A, Lilford RJ, and English M. Appropriateness of clinical severity 
classification of new WHO childhood pneumonia guidance: a multi-hospital, 
retrospective, cohort study. Lancet Glob Heal. 2018;6(1):e74–83. 
In this analysis of more than 16,000 inpatient pneumonia episodes, I explore the 
factors that may account for high mortality in a setting where comorbidities are 
common, and coverage of pneumococcal and Haemophilus influenzae type B 
conjugate vaccines is high.  
The findings of this study attempt to refine the WHO pneumonia case management 
algorithm by identifying sub-populations of children at high risk of death who would, 
under current guidance, be classified as low risk and managed as outpatients.  
I apply logistic regression to model risks for mortality, using multiple imputation with 
appropriate sensitivity analyses to account for missing data. I also calculate absolute 
risks of death for sub-groups of children categorized as ‘non-severe pneumonia’ 
presenting with pre-specified clinical features that would not result in a ‘severe’ 
classification according to WHO criteria. Data from all children hospitalised with 
pneumonia at 14 public hospitals in Kenya between 1 March 2014 and 29 February 
2016 were included. Among all children with pneumonia 832/16031 (5·2 percent) 
died. Mortality was considerably higher in those with severe pneumonia (14.2 
percent) compared with non-severe pneumonia (2.7 percent). Among children with 
non-severe pneumonia, severe pallor (adjusted risk ratio (aRR) 5.8; 95% CI 5.1–6.7), 
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mild/moderate pallor (aRR 3.6; 95% CI 3.2–4.0), and weight-for-age Z (WAZ) score 
<-3SD (aRR 3.9; 95% CI 3.5–4.4) were strongly and independently associated with 
increased mortality. Children classified as non-severe pneumonia with any of these 
three signs were also observed to have absolute risks of death that were comparable 
to those fulfilling the WHO criteria for severe pneumonia. 
This study has important implications in the context of the current WHO policy 
environment advocating for outpatient treatment for all but those children with a 
limited set of clinical signs that currently define severe pneumonia. While severe 
pallor would warrant hospitalisation, the current recommendations for case 
management do not consider very low WAZ or mild/moderate pallor as important risk 
factors. I note that 1272/12025 (10.6 percent) children defined as having non-severe 
pneumonia in this study with either of these two risk factors would be expected to be 
managed at home under current recommendations. 
In conclusion, I affirm that WHO recommendations misclassify some children as 
having mild disease suitable for home-based care. I also call for clinicians to exercise 
caution in decision making when considering the appropriate management for 
children with non-severe pneumonia in the presence of the risk factors identified. 
8 Discussion 
This thesis describes the journey taken to generate revised evidence-based 
guidelines for the care of children with pneumonia in Kenya, even as the WHO issued 
its global guidance that remains contested in many sub-Saharan African countries. 
The five studies collectively illustrate some of the key issues facing practising 
clinicians, researchers and policymakers in the region, regarding the pneumonia 
case management guidelines. I further attempt to address some of the questions 
raised and highlight the major gaps in evidence for future research. 
 
Until recently, guideline development was an opaque process that varied widely 
across institutions (59, 60). The growing demand for transparent, systematic 
approaches for guideline development has resulted in new challenges for institutions 
responsible for generating and updating clinical guidelines. These challenges are 
particularly apparent in settings where resources and technical expertise are limited. 
In Kenya, an adapted form of the GRADE system has been applied to update the 
national paediatric guidelines on several occasions since it was first attempted more 
than five years ago (61).  
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Pragmatic trials are purposefully designed to generate evidence that can be 
generalized to real-world settings. This quality is an important consideration when 
determining the usefulness of study findings for decision making (62) and has been 
a key concern among policymakers debating the appropriateness of adopting the 
revised WHO pneumonia recommendations (13). PRECIS-2 (an improvement on the 
2009 PRECIS tool (63)) is a simple tool comprising nine domains developed to aid 
trialists in designing studies aligned to the purpose for which they are designed (64). 
Historically, clinical trials have been categorised into two distinct descriptions: 
explanatory or pragmatic (65). This approach has been criticised for being over-
simplistic (66). Consequently, there has been a shift towards describing studies in 
terms of where they lie along the efficacy-effectiveness spectrum. The PRECIS-2 
tool assigns a score out of 5 points to each of the nine domains, with a score of 1 
representing very explanatory and 5, very pragmatic. In Figure 2, this tool is used to 
evaluate our trial comparing amoxicillin versus benzyl penicillin for severe childhood 
pneumonia with an overall conclusion that the trial was moderately pragmatic.  
 
Figure 2: PRECIS-2 wheel for amoxicillin versus benzyl penicillin clinical trial 
To mitigate the potential for subjective assignment of scores, a table displaying the 
rationale for the allocated scores is provided in Table 3.
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Table 3: Rationale supporting PRECIS-2 scores for amoxicillin versus benzyl penicillin clinical trial 
PRECIS-2 Domain Score* Rationale 
1. Eligibility  5 Eligibility criteria were flexible. A majority of the participants had one or more comorbidity. Additional 
analyses (reported separately) confirmed representativeness of the study participants to other patients 
receiving routine care at the study sites 
2. Recruitment 4 Participants were recruited by an individual clinician on site at the point of admission for general hospital 
patients 
3. Setting 5 The study was conducted in the inpatient departments of public hospitals alongside routine care for non-
study patients  
4. Organization 4 The core team conducting the trial (including the principal investigator), had very limited experience 
conducting clinical trials. Some support was provided remotely by an established clinical trial unit  
5. Flexibility: 
delivery 
5 The intervention was delivered by caregivers of study patients with no formal supervision provided. This 
was identical to what would be done under routine care 
6. Flexibility: 
adherence 
3 Logs were maintained to determine quantities of study drug administered to the study patients. 
Inappropriate administration of study drugs was captured as protocol violations 
7. Follow up 3 One study clinician was responsible for overall follow up of study patients. However, clinicians delivering 
care to non-study patients were not explicitly restricted from making decisions on changes in 
management for study patients. Outpatient follow up for the secondary outcome following hospital 
discharge was limited to a telephone call or a single return visit 14 days after recruitment  
8. Primary 
outcome 
5 The primary outcome, treatment failure, was highly relevant to participants as it included the 
development of signs of clinical deterioration including death. 
9. Primary 
analysis 
3 Data were collected on an online database which was monitored actively by the study team. Reasonable 
effort was made to ensure completeness of data. Both intention to treat and per protocol analyses were 
undertaken 
* Score of 5 = very pragmatic;  1 = very explanatory
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In the most recent review of the national paediatric guidelines, primary evidence from 
the clinical trial presented in this thesis (67) was presented to the guideline panel 
considering the revision of the pneumonia treatment protocol. In contrast with a very 
similar exercise conducted in 2010, described in the first paper of this thesis (68), the 
panellists issued a strong recommendation based on what was concluded to be high-
quality evidence in support for the use of amoxicillin in place of benzyl penicillin for 
children with indrawing pneumonia without danger signs. This recommendation 
ultimately resulted in the recent revision of the Kenya national policy for pneumonia 
treatment (69) (Table 4).  
Table 4: Kenyan Ministry of Health (2016) and WHO (post-2013) guidelines for 
the management of children aged 2 - 59 months with a cough and/or difficulty 
breathing 
Syndrome* Clinical Signs Recommended Antibiotic 
Treatment  
Severe 
pneumonia 
Any one of: cyanosis, grunting, 
oxygen saturation<90 percent, 
inability to drink/breastfeed, altered 
consciousness 
Inpatient treatment  
Benzyl penicillin/ ampicillin and 
gentamicin  
(plus high dose co-trimoxazole for 
all HIV-exposed infants) 
Pneumonia No signs of severe pneumonia 
AND 
Indrawing OR 
Outpatient treatment 
Oral amoxicillin 
 Fast breathing  (RR≥50/min if age 2-
11months; ≥40/min if age 12-59 
months) 
(if HIV-exposed with indrawing, treat 
as severe pneumonia) 
*For a child without stridor, severe acute malnutrition or signs of meningitis 
 
Availing guidelines alone, however, has been shown to be insufficient for changing 
clinical practice in a range of settings, particularly where health systems are weak (70-
74). A recently concluded clinical trial seeks to evaluate alternative approaches to 
providing feedback to health care workers to promote the uptake of the new guidelines 
for the management of indrawing pneumonia using oral amoxicillin (ClinicalTrials.gov 
registration Identifier NCT02817971).  
 
    
 
19 
In September 2015, world leaders adopted the Sustainable Development Goals (SDG) 
– a comprehensive framework that defines the global development agenda from 2016 
to 2030 (75). Among the 17 goals, SDG 3 aims to end preventable deaths of newborns 
and children, and to reduce the under-5 mortality, to at least as low as 25 per 1,000 live 
births by 2030 (against an estimated rate of 46 per 1,000 live births in 2013 (1)). To 
achieve this ambitious target, governments and development partners must align their 
efforts towards addressing the leading causes of mortality and in regions where most 
deaths occur. Pneumonia has traditionally been referred to as the neglected childhood 
killer (76-78), receiving disproportionately less public attention and resources than other 
global public health priorities such as HIV and malaria (79). Recent initiatives such as 
the WHO/UNICEF-led integrated Global Action Plan for the Prevention and Control of 
Pneumonia and Diarrhoea (GAPPD) (80) and the HIFA2015/CHILD2015 Childhood 
Pneumonia Project, sponsored by the British Medical Association (81), have been 
specifically borne out of the urgent need to increase awareness and action on childhood 
pneumonia. Ultimately, more resources are needed to support research to generate 
relevant evidence to inform the development of effective policies to decisively address 
the burden of pneumonia. The apparent responsiveness of Kenyan policymakers to new 
evidence during the development of pneumonia guideline recommendations is a 
promising sign for researchers considering the various clinical questions whose existing 
recommendations are based on evidence that is either weak or outdated.  
 
8.1 Limitations 
A major weakness of studies undertaken in this thesis was the use of routine clinical 
data (studies (iv) and (v)). The accuracy of the recorded data could not be ascertained, 
and missing data were commonly encountered in the observational studies. To mitigate 
this effect, multiple imputation by chained equations was performed for variables 
included in the analyses that relied on routinely-collected clinical data. The efficiency of 
this approach was enhanced by the large sample sizes of the populations studied. 
 
Reliable data on microbiological aetiology linked to clinical diagnosis and ultimately 
outcomes may have addressed the objective to examine the effectiveness of the 
pneumonia treatment guidelines more comprehensively. This was however not feasible 
with the limited resources available and the challenges of accurately determining the 
aetiology for cases of childhood pneumonia, even where resources are unrestricted. 
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The results showing overall low risks of treatment failure and mortality for children with 
indrawing pneumonia, comparable to other settings are however reassuring and offer 
indirect information on the effectiveness of the existing guidelines in both routine care 
and clinical trial settings.  
 
The hospital where study (ii) was conducted is a large tertiary teaching hospital in the 
Kenyan capital city, while the other studies (iii), (iv) and (v), were conducted in district-
level hospitals that were part of a clinical network in which a feedback-driven intervention 
to improve care for hospitalised children has been taking place since 2013 (15). It may, 
therefore, be argued that the study sites were not strictly representative of routine care 
settings, particularly for study (v), which included patients hospitalised between 2014 
and 2016 (during the period of the network intervention). I, however, argue that the 
availability of data of reasonable quality to reliably address the study questions, that 
would otherwise be unavailable through the routine health information system in other 
hospitals outside the network (82), far outweighs the potential intervention effect at the 
study sites. 
9 Areas for further research 
Among the research questions that are likely to be of interest to policymakers in the 
immediate future are: 
(i) What is the most effective management for children with pneumonia presenting 
with danger signs in low-resource settings?  
Case fatality among children with pneumonia presenting with one or more danger signs 
was greater than 10 percent in two studies of Kenyan children reported in this thesis, 
even among those who received guideline-recommended antibiotics. High mortality may 
be attributable to late presentation attributable to delays in care seeking and/or 
inefficiencies in the referral system, diminished efficacy of recommended treatments 
(factors related to the interactions between patient, pathogen and drug), misdiagnosis 
(referred to in (ii) below) or inadequate aspects of supportive care (such as feeding, 
fluids, oxygen or capacity to provide intensive care and monitoring). The latter possibility 
is of particular interest as the burden of “pneumonia” cases attributable to bacterial 
causes declines, and a larger fraction of severe presentations are increasingly likely to 
be due to diagnoses presenting with respiratory distress indistinguishable from true 
pneumonia such as metabolic acidosis in sepsis, dehydration or severe malaria or 
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decompensated anaemia. The much-needed evidence to address these questions 
highlights the need for locally conducted high quality pragmatic clinical trials of 
alternative interventions for the care of critically ill children in resource-limited settings. 
 
(ii) How useful are the WHO clinical signs for determining the need for, and choice 
of antibiotics for children with severe pneumonia? 
As a result of the introduction of conjugate vaccines, there are theoretical concerns 
regarding the diminishing utility of clinical algorithms that were already known to have 
modest specificity to detect bacterial pneumonia. As a consequence, there need to test 
new approaches to classify pneumonia for the purpose of informing appropriate 
treatment. Related to this focus is a growing interest in the development and testing of 
low-cost point-of-care diagnostics, with the ability to discriminate between bacterial 
pneumonia and other common causes of acute respiratory distress with reasonable 
accuracy and reliability. As the campaign for rational antibiotic use continues to grow, 
linked to fears of rising levels of antibiotic resistance, this gap in evidence is likely to 
continue to gain attention.  
10 References 
1. You D, Hug L, Ejdemyr S, Idele P, Hogan D, Mathers C, et al. Global, regional, 
and national levels and trends in under-5 mortality between 1990 and 2015, with 
scenario-based projections to 2030: a systematic analysis by the UN Inter-agency 
Group for Child Mortality Estimation. Lancet. 2015;386(10010):2275-86. 
2. Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, et al. Global, regional, and 
national causes of child mortality in 2000-13, with projections to inform post-2015 
priorities: an updated systematic analysis. Lancet. 2015;385(9966):430-40. 
3. WHO WHO. Acute Respiratory Infections in Children; Case Management in 
Small Hospitals in Developing Countries. WHO/ARI905/ WHO. 1990. 
4. Sazawal S, Black R. Pneumonia Case Management Trials Group. Effect of 
pneumonia case management on mortality in neonates, infants, and preschool 
children: a meta-analysis of community-based trials. Lancet. 2003;3:547-56. 
5. Niessen LW, ten Hove A, Hilderink H, Weber M, Mulholland K, Ezzati M. 
Comparative impact assessment of child pneumonia interventions. Bulletin of the 
World Health Organization. 2009;87(6):472-80. 
6. Jones G, Steketee R, Black R, Bhutta Z, Morris S. How many deaths can we 
prevent this year? Lancet. 2003;362:65-71. 
7. World Health Organization. Pocket book of hospital care for children: 
Guidelines for the managemant of common illnesses with limited resources. Geneva 
2005. 
8. World Health Organization. Recommendations for management of common 
childhood conditions: evidence for technical update of pocket book recommendations: 
newborn conditions, dysentery, pneumonia, oxygen use and delivery, common causes 
    
 
22 
of fever, severe acute malnutrition and supportive care. Geneva: World Health 
Organization; 2012. 
9. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. 
GRADE: an emerging consensus on rating quality of evidence and strength of 
recommendations. Bmj. 2008;336(7650):924-6. 
10. Addo-Yobo E, Chisaka N, Hassan M, Hibberd P, Lozano JM, Jeena P, et al. 
Oral amoxicillin versus injectable penicillin for severe pneumonia in children aged 3 to 
59 months: a randomised multicentre equivalency study. Lancet. 
2004;364(9440):1141-8. 
11. Atkinson M, Lakhanpaul M, Smyth A, Vyas H, Weston V, Sithole J, et al. 
Comparison of oral amoxicillin and intravenous benzyl penicillin for community 
acquired pneumonia in children (PIVOT trial): a multicentre pragmatic randomised 
controlled equivalence trial. Thorax. 2007;62(12):1102-6. 
12. Hazir T, Fox LM, Nisar YB, Fox MP, Ashraf YP, MacLeod WB, et al. 
Ambulatory short-course high-dose oral amoxicillin for treatment of severe pneumonia 
in children: a randomised equivalency trial. Lancet. 2008;371(9606):49-56. 
13. Mulholland K, Carlin JB, Duke T, Weber M. The challenges of trials of 
antibiotics for pneumonia in low-income countries. The Lancet Respiratory medicine. 
2014;2(12):952-4. 
14. English M, Esamai F, Wasunna A, Were F, Ogutu B, Wamae A, et al. 
Assessment of inpatient paediatric care in first referral level hospitals in 13 districts in 
Kenya. The Lancet. 2004;363:1948-53. 
15. Ayieko P, Ogero M, Makone B, Julius T, Mbevi G, Nyachiro W, et al. 
Characteristics of admissions and variations in the use of basic investigations, 
treatments and outcomes in Kenyan hospitals within a new Clinical Information 
Network. Arch Dis Child. 2016;101(3):223-9. 
16. Nair H, Simoes EA, Rudan I, Gessner BD, Azziz-Baumgartner E, Zhang JS, et 
al. Global and regional burden of hospital admissions for severe acute lower 
respiratory infections in young children in 2010: a systematic analysis. Lancet. 
2013;381(9875):1380-90. 
17. Marchant CD, Carlin SA, Johnson CE, Shurin PA. Measuring the comparative 
efficacy of antibacterial agents for acute otitis media: the "Pollyanna phenomenon". J 
Pediatr. 1992;120(1):72-7. 
18. Mulholland K, Carlin J, Duke T, Weber M. Antibiotic trials for community-
acquired pneumonia--authors' reply. The Lancet Respiratory medicine. 2015;3(3):e5. 
19. Clinical management of acute respiratory infections in children: a WHO 
memorandum. Bulletin of the World Health Organization. 1981;59(5):707-16. 
20. Shann F, Hart K, Thomas D. Acute lower respiratory tract infections in children: 
Possible criteria for selection of patients for antibiotic therapy and hospital admission. 
Bulletin of the World Health Organization. 1984;62(5):749-53. 
21. Shann F. Clinical signs of pneumonia in children. Lancet. 1989;1(8639):673. 
22. Ayieko P, English M. Case management of childhood pneumonia in developing 
countries. Pediatr Infect Dis J. 2007;26(5):432-40. 
23. Grant GB, Campbell H, Dowell SF, Graham SM, Klugman KP, Mulholland EK, 
et al. Recommendations for treatment of childhood non-severe pneumonia. The 
Lancet Infectious diseases. 2009;9(3):185-96. 
24. Hazir T, Qazi SA, Nisar YB, Maqbool S, Asghar R, Iqbal I, et al. Can WHO 
therapy failure criteria for non-severe pneumonia be improved in children aged 2-59 
months? The international journal of tuberculosis and lung disease : the official journal 
of the International Union against Tuberculosis and Lung Disease. 2006;10(8):924-31. 
    
 
23 
25. Tsolia MN, Psarras S, Bossios A, Audi H, Paldanius M, Gourgiotis D, et al. 
Etiology of community-acquired pneumonia in hospitalized school-age children: 
evidence for high prevalence of viral infections. Clin Infect Dis. 2004;39(5):681-6. 
26. Hammitt LL, Kazungu S, Morpeth SC, Gibson DG, Mvera B, Brent AJ, et al. A 
preliminary study of pneumonia etiology among hospitalized children in Kenya. Clin 
Infect Dis. 2012;54 Suppl 2:S190-9. 
27. Gilani Z, Kwong YD, Levine OS, Deloria-Knoll M, Scott JA, O'Brien KL, et al. A 
literature review and survey of childhood pneumonia etiology studies: 2000-2010. Clin 
Infect Dis. 2012;54 Suppl 2:S102-8. 
28. Shann F. Etiology of severe pneumonia in children in developing countries. 
Ped Inf Dis J. 1986:247-52. 
29. Selwyn B, J on behalf of the co-ordinated data group of Bostid researchers. 
The epidemiology of acute respiratory infections in young children: comparison of 
findings from several developing countries. Reviews of Infectious Diseases. 
1990;12(Supplement 8):S870-88. 
30. Levine OS, Bhat N, Crawley J, Deloria-Knoll M, DeLuca AN, Driscoll AJ, et al. 
Pneumonia etiology research for child health. Introduction. Clin Infect Dis. 2012;54 
Suppl 2:S87-8. 
31. Sonego M, Pellegrin MC, Becker G, Lazzerini M. Risk factors for mortality from 
acute lower respiratory infections (ALRI) in children under five years of age in low and 
middle-income countries: a systematic review and meta-analysis of observational 
studies. PLoS One. 2015;10(1):e0116380. 
32. Cutts F, Zaman S, Enwere G, Jaffar S, Levine O, Okoko J, et al. Efficacy of 
nine-valent pneumococcal conjugate vaccine against pneumonia and invasive 
pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled 
trial. Lancet. 2005;365(9465):1139-46. 
33. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. 
Decline in pneumonia admissions after routine childhood immunisation with 
pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 
2007;369(9568):1179-86. 
34. Klugman K, Madhi S, Huebner R, Kohberger R, Mbelle N, Pierce N, et al. A 
trial of a 9-valent pneumoccoccal conjugate vaccine in children with and those without 
HIV infection. N Engl J Med. 2003;349:1341-8. 
35. O'Brien K, Moulton L, Reid R, Weatherholtz R, Oski J, Brown L, et al. Effficacy 
and safety of seven-valent conjugate pnemococcal vaccine in American Indian 
children: a group randomised trial. The Lancet. 2003;362:355-61. 
36. Cowgill KD, Ndiritu M, Nyiro J, Slack MP, Chiphatsi S, Ismail A, et al. 
Effectiveness of Haemophilus influenzae type b Conjugate vaccine introduction into 
routine childhood immunization in Kenya. JAMA. 2006;296(6):671-8. 
37. Scott JA, English M. What are the implications for childhood pneumonia of 
successfully introducing Hib and pneumococcal vaccines in developing countries? 
PLoS Med. 2008;5(4):e86. 
38. Kenya National Bureau of Statistics (KNBS) and ICF Macro. Kenya 
Demographic Health Survey 2014. Calverton, Maryland: KNBS and ICF Macro; 2014. 
39. Chisti MJ, Hossain MI, Malek MA, Faruque AS, Ahmed T, Salam MA. 
Characteristics of severely malnourished under-five children hospitalized with 
diarrhoea, and their policy implications. Acta Paediatr. 2007;96(5):693-6. 
40. Chisti MJ, Salam MA, Sharifuzzaman, Pietroni MA. Occult pneumonia: an 
unusual but perilous entity presenting with severe malnutrition and dehydrating 
diarrhoea. Journal of health, population, and nutrition. 2009;27(6):808-12. 
    
 
24 
41. Chisti MJ, Tebruegge M, La Vincente S, Graham SM, Duke T. Pneumonia in 
severely malnourished children in developing countries - mortality risk, aetiology and 
validity of WHO clinical signs: a systematic review. Trop Med Int Health. 
2009;14(10):1173-89. 
42. Chisti MJ, Graham SM, Duke T, Ahmed T, Faruque AS, Ashraf H, et al. Post-
discharge mortality in children with severe malnutrition and pneumonia in Bangladesh. 
PLoS One. 2014;9(9):e107663. 
43. Rytter MJ, Kolte L, Briend A, Friis H, Christensen VB. The immune system in 
children with malnutrition--a systematic review. PLoS One. 2014;9(8):e105017. 
44. Waterlow JC, Alleyne GA. Protein malnutrition in children: advances in 
knowledge in the last ten years. Adv Protein Chem. 1971;25:117-241. 
45. Tomkins AM, Garlick PJ, Schofield WN, Waterlow JC. The combined effects of 
infection and malnutrition on protein metabolism in children. Clin Sci (Lond). 
1983;65(3):313-24. 
46. Yoon PW, Black RE, Moulton LH, Becker S. The effect of malnutrition on the 
risk of diarrheal and respiratory mortality in children < 2 y of age in Cebu, Philippines. 
The American journal of clinical nutrition. 1997;65(4):1070-7. 
47. Gray DM, Zar HJ. Community-acquired pneumonia in HIV-infected children: a 
global perspective. Current opinion in pulmonary medicine. 2010;16(3):208-16. 
48. McNally LM, Jeena PM, Gajee K, Thula SA, Sturm AW, Cassol S, et al. Effect 
of age, polymicrobial disease, and maternal HIV status on treatment response and 
cause of severe pneumonia in South African children: a prospective descriptive study. 
Lancet. 2007;369(9571):1440-51. 
49. Reed C, Madhi SA, Klugman KP, Kuwanda L, Ortiz JR, Finelli L, et al. 
Development of the Respiratory Index of Severity in Children (RISC) score among 
young children with respiratory infections in South Africa. PLoS ONE. 
2012;7(1):e27793. 
50. Jeena P, Thea DM, MacLeod WB, Chisaka N, Fox MP, Coovadia HM, et al. 
Failure of standard antimicrobial therapy in children aged 3-59 months with mild or 
asymptomatic HIV infection and severe pneumonia. Bulletin of the World Health 
Organization. 2006;84(4):269-75. 
51. Cohen C, Walaza S, Moyes J, Groome M, Tempia S, Pretorius M, et al. 
Epidemiology of viral-associated acute lower respiratory tract infection among children 
<5 years of age in a high HIV prevalence setting, South Africa, 2009-2012. Pediatr 
Infect Dis J. 2015;34(1):66-72. 
52. Chintu C, Mudenda V, Lucas S, Nunn A, Lishimpi K, Maswahu D, et al. Lung 
diseases at necropsy in African children dying from respiratory illnesses: a descriptive 
necropsy study. Lancet. 2002;360(9338):985-90. 
53. National AIDS and STI Control Programme. Kenya AIDS Indicator Survey 2012 
(Preliminary Report). Nairobi, Kenya: Ministry of Health; 2013. 
54. Cohen C, Moyes J, Tempia S, Groome M, Walaza S, Pretorius M, et al. 
Epidemiology of Acute Lower Respiratory Tract Infection in HIV-Exposed Uninfected 
Infants. Pediatrics. 2016. 
55. Mussi-Pinhata MM, Freimanis L, Yamamoto AY, Korelitz J, Pinto JA, Cruz ML, 
et al. Infectious disease morbidity among young HIV-1-exposed but uninfected infants 
in Latin American and Caribbean countries: the National Institute of Child Health and 
Human Development International Site Development Initiative Perinatal Study. 
Pediatrics. 2007;119(3):e694-704. 
    
 
25 
56. Marinda E, Humphrey JH, Iliff PJ, Mutasa K, Nathoo KJ, Piwoz EG, et al. Child 
mortality according to maternal and infant HIV status in Zimbabwe. Pediatr Infect Dis 
J. 2007;26(6):519-26. 
57. Slogrove A, Reikie B, Naidoo S, De Beer C, Ho K, Cotton M, et al. HIV-
exposed uninfected infants are at increased risk for severe infections in the first year of 
life. Journal of tropical pediatrics. 2012;58(6):505-8. 
58. Afran L, Garcia Knight M, Nduati E, Urban BC, Heyderman RS, Rowland-
Jones SL. HIV-exposed uninfected children: a growing population with a vulnerable 
immune system? Clin Exp Immunol. 2014;176(1):11-22. 
59. Turner T, Misso M, Harris C, Green S. Development of evidence-based clinical 
practice guidelines (CPGs): comparing approaches. Implementation science : IS. 
2008;3:45. 
60. Pilling S. History, context, process, and rationale for the development of clinical 
guidelines. Psychol Psychother. 2008;81(Pt 4):331-50. 
61. English M, Opiyo N. Getting to grips with GRADE-perspective from a low-
income setting. Journal of clinical epidemiology. 2011;64(7):708-10. 
62. Rothwell P. External validity of randomised controlled trials: " to whom do the 
results of this trial apply? Lancet. 2005;365:82-93. 
63. Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, 
et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help 
trial designers. Journal of clinical epidemiology. 2009;62(5):464-75. 
64. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The 
PRECIS-2 tool: designing trials that are fit for purpose. Bmj. 2015;350:h2147. 
65. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical 
trials. J Chronic Dis. 1967;20(8):637-48. 
66. Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, et al. 
Improving the reporting of pragmatic trials: an extension of the CONSORT statement. 
Bmj. 2008;337:a2390. 
67. Agweyu A, Gathara D, Oliwa J, Muinga N, Edwards T, Allen E, et al. Oral 
amoxicillin versus benzyl penicillin for severe pneumonia among kenyan children: a 
pragmatic randomized controlled noninferiority trial. Clin Infect Dis. 2015;60(8):1216-
24. 
68. Agweyu A, Opiyo N, English M. Experience developing national evidence 
based clinical guidelines for childhood pneumonia in a low-income setting - making the 
GRADE? BMC Pediatr. 2012;12(1):1. 
69. Government of Kenya (Ministry of Health). Basic Paediatric Protocols. 4th ed. 
Nairobi 2016. 
70. Reyburn H, Mwakasungula E, Chonya S, Mtei F, Bygbjerg I, Poulsen A, et al. 
Clinical assessment and treatment in paediatric wards in the north-east of the United 
Republic of Tanzania. Bulletin of the World Health Organization. 2008;86(2):132-9. 
71. Febir LG, Baiden FE, Agula J, Delimini RK, Akpalu B, Tivura M, et al. 
Implementation of the integrated management of childhood illness with parasitological 
diagnosis of malaria in rural Ghana: health worker perceptions. Malar J. 2015;14:174. 
72. Shayo EH, Vaga BB, Moland KM, Kamuzora P, Blystad A. Challenges of 
disseminating clinical practice guidelines in a weak health system: the case of HIV and 
infant feeding recommendations in Tanzania. Int Breastfeed J. 2014;9(1):188. 
73. Ayieko P, Ntoburi S, Wagai J, Opondo C, Opiyo N, Migiro S, et al. A 
multifaceted intervention to implement guidelines and improve admission paediatric 
care in Kenyan district hospitals: a cluster randomised trial. PLoS Med. 
2011;8(4):e1001018. 
    
 
26 
74. Freemantle N, Harvey EL, Wolf F, Grimshaw JM, Grilli R, Bero LA. Printed 
educational materials: effects on professional practice and health care outcomes. 
Cochrane Database Syst Rev. 2000(2):CD000172. 
75. United Nations. Sustainable Development Goals, 17 goals to transform our 
world. New York [Available from: http://www.un.org/sustainabledevelopment/. 
76. Shann F. A neglected cause of death. Pneumonia in children. Nurs RSA. 
1987;2(3):39-40. 
77. Paynter S, Ware RS, Weinstein P, Williams G, Sly PD. Childhood pneumonia: 
a neglected, climate-sensitive disease? Lancet. 2010;376(9755):1804-5. 
78. The United Nations Children’s Fund (UNICEF)/World Health Organization 
(WHO). Pneumonia: The forgotten killer of children. New York; 2006. 
79. Greenwood BM, Weber MW, Mulholland K. Childhood pneumonia--preventing 
the worlds biggest killer of children. Bulletin of the World Health Organization. 
2007;85(7):502-3. 
80. The World Health Organization (WHO)/United Nations Children’s Fund 
(UNICEF). End preventable deaths: Global Action Plan for Prevention and Control of 
Pneumonia and Diarrhoea. Geneva; 2013. 
81. Global Healthcare Information Network. HIFA2015/CHILD2015 Childhood 
Pneumonia Project. Oxfordshire [Available from: http://www.hifa2015.org/. 
82. Kihuba E, Gathara D, Mwinga S, Mulaku M, Kosgei R, Mogoa W, et al. 
Assessing the ability of health information systems in hospitals to support evidence-
informed decisions in Kenya. Glob Health Action. 2014;7:24859. 
 
 
  
    
 
27 
11 Appendices 
 
11.1 Statements of contribution 
 
Paper I: Experience developing national evidence-based clinical guidelines for 
childhood pneumonia in a low-income setting - making the GRADE?  
Ambrose Agweyu, Newton Opiyo and Mike English 
 
Ambrose Agweyu, supported by Mike English and Newton Opiyo, was primarily responsible for 
the systematic review of pneumonia case management. Ambrose Agweyu produced the first draft 
of the report on use of GRADE that was further developed with input from Mike English and 
Newton Opiyo. All authors reviewed and approved the final version of the manuscript. 
 
I agree that Ambrose Agweyu made the aforementioned contribution to the paper. 
Newton Opiyo  …………………………………… Date: 19 May 2017 
Mike English  …………………………………… Date: 19 May 2017 
 
  
    
 
28 
Paper II: Prevalence and correlates of treatment failure among Kenyan children 
hospitalised with severe community-acquired pneumonia: a prospective study of 
the clinical effectiveness of WHO pneumonia case management guidelines. 
Ambrose Agweyu, Minnie Kibore, Lina Digolo, Caroline Kosgei, Virginia Maina, Samson 
Mugane, Sarah Muma, John Wachira, Mary Waiyego,  and Elizabeth Obimbo. 
 
Ambrose Agweyu led the development of the study protocol. All of the authors 
participated in the design of the study and collection of data. Ambrose Agweyu produced 
the initial draft of the manuscript. All the co-authors reviewed and approved the final 
report prior to submission. 
 
I agree that Ambrose Agweyu made the aforementioned contribution to the paper. 
Minnie Kibore  …………………………………… Date: 19 May 2017 
 
Lina Digolo  …………………………………… Date: 19 May 2017 
Caroline Kosgei …………………………………… Date: 19 May 2017 
 
Virginia Maina  …………………………………… Date: 19 May 2017 
 
Samson Mugane  …………………………………… Date: 19 May 2017 
 
John Wachira   …………………………………… Date: 19 May 2017 
 
Mary Waiyego  …………………………………… Date: 19 May 2017 
Elizabeth Obimbo  …………………………………… Date: 19 May 2017 
    
 
29 
Paper III: Oral amoxicillin versus benzyl penicillin for severe pneumonia among 
Kenyan children: a pragmatic randomized controlled noninferiority trial. 
Ambrose Agweyu, David Gathara, Jacquie Oliwa, Naomi Muinga, Tansy Edwards, 
Elizabeth Allen, Elizabeth Obimbo, and Mike English on behalf of the Severe Pneumonia 
Study Group. 
 
Ambrose Agweyu led the design of the study with input from, David Gathara, Jacquie 
Oliwa, Naomi Muinga, Elizabeth Allen, Elizabeth Obimbo, and Mike English participated 
in the design of the study and collection of data. Ambrose Agweyu produced the initial 
draft of the manuscript that was further developed by Mike English, Elizabeth Obimbo, 
and Elizabeth Allen, the trial statistician, who oversaw the analyses. Members of the 
wider Severe Pneumonia Study Group contributed to the planning and conduct of the 
study as co-investigators within the Ministry of Health, as site principal investigators, or 
as study clinicians. All authors reviewed and approved the final manuscript. 
 
I agree that Ambrose Agweyu made the aforementioned contribution to the paper. 
 
David Gathara  …………………………………… Date: 19 May 2017 
 
Jacquie Oliwa  …………………………………… Date: 19 May 2017 
 
Naomi Muinga  …………………………………… Date: 19 May 2017 
 
Tansy Edwards …………………………………… Date: 19 May 2017 
 
 
Elizabeth Allen …………………………………… Date: 19 May 2017 
    
 
30 
 
 Elizabeth Obimbo  …………………………………… Date: 19 May 2017 
 
Mike English  …………………………………… Date: 19 May 2017 
 
 
  
    
 
31 
Paper IV: Comparable outcomes among trial and nontrial participants in a clinical 
trial of antibiotics for childhood pneumonia: a retrospective cohort study 
Ambrose Agweyu, Jacquie Oliwa, David Gathara, Naomi Muinga, Elizabeth Allen, 
Richard J. Lilford, and Mike English  
 
Ambrose Agweyu conceived the study supported by Jacquie Oliwa, David Gathara, Naomi 
Muinga, Elizabeth Allen, Richard Lilford, and Mike English. Ambrose Agweyu, Jacquie Oliwa, 
David Gathara, Naomi Muinga, and Mike English were involved in collection of data. Ambrose 
Agweyu conducted analyses and produced the initial draft of the manuscript that was further 
developed by Richard J. Lilford, Mike English, and Elizabeth Allen. All authors reviewed and 
approved the final version of the manuscript. 
 
I agree that Ambrose Agweyu made the aforementioned contribution to the paper. 
 
Jacquie Oliwa  …………………………………… Date: 19 May 2017. 
David Gathara  …………………………………… Date: 19 May 2017 
 
Naomi Muinga  …………………………………… Date: 19 May 2017 
 
Elizabeth Allen …………………………………… Date: 19 May 2017 
  
Richard J. Lilford …………………………………… Date: 19 May 2017 
 
Mike English  …………………………………… Date: 19 May 2017 
  
    
 
32 
Paper V: Appropriateness of clinical severity classification of new World Health 
Organization (WHO) childhood pneumonia guidance: a multi-hospital 
retrospective cohort study 
Ambrose Agweyu, Richard J. Lilford, and Mike English on behalf of the Clinical Information 
Network Author Group 
 
Ambrose Agweyu, Richard J. Lilford, and Mike English jointly conceived the study. Ambrose 
Agweyu undertook the analyses with support from Richard Lilford, and Mike English. 
Ambrose Agweyu drafted the manuscript with input from Richard Lilford, and Mike English. 
The wider Clinical Information Network Group contributed to the design of the data 
collection tools, conduct of the work, collection of data and data quality assurance that 
form the basis of this report. All authors review and approved the final manuscript. 
 
I agree that Ambrose Agweyu made the aforementioned contribution to the paper. 
 
Richard J. Lilford …………………………………… Date: 19 May 2017 
 
Mike English  …………………………………… Date: 19 May 2017 
 
